Czech Republic: Tax base reduction for bonuses paid by pharmaceutical companies to insurance companies

Reduction of the tax base can be performed by a pharmaceutical company that pays a bonus to a health insurance company

Tax base reduction for bonuses paid by pharmaceutical companies to insurance companies

The General Financial Directorate (GFD) confirmed that the reduction of the tax base can be performed by a pharmaceutical company that pays a bonus to a health insurance company regardless of whether the pharmaceutical company holds a decision on the registration of medicinal products and on their placement on the Czech market.

Overview

Pharmaceutical companies (drug manufacturers) supply medicines to distributors who dispense them to patients either directly or through other healthcare providers. If the patient is insured with a health insurance company, it is the insurance company that pays for the medicine. The latter has a contract to limit the risks/costs associated with the reimbursement of the medicines with the drug manufacturer (pharmaceutical company), which holds a decision on the registration of medicinal products in the Czech Republic in compliance with the Medicines Act. Under this contract, the drug manufacturer pays a bonus in arrears to the health insurance company once the agreed limit of the insurance company’s annual cost for the medicine is reached.

The holder of the decision on the registration of medicinal products may place medicines on the Czech market directly or through a pharmaceutical importer (i.e., the registration holder and the importer are two different persons). When a health insurance company enters into a contract to limit the risks/costs associated with the reimbursement of medicinal products directly with the importer, it is the importer’s tax base that will be reduced upon the payment of the bonus to the health insurance company, as the importer is economically burdened by the payment of the bonus.

However, if a health insurance company has concluded a contract to limit the risks/costs associated with the reimbursement of medicinal products with the registration holder, but the bonus is in fact paid by the importer, doubts have arisen in practice as to who should reduce the tax base on account of the paid bonus paid.

The GFD confirmed that if the importer paying the bonus is in a contractual relationship with the registration holder, the importer may correct the tax base when the bonus is paid to the health insurance company.

Read a January 2022 report prepared by the KPMG member firm in the Czech Republic

 

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization. KPMG International Limited is a private English company limited by guarantee and does not provide services to clients. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.